July 1, 2021 | BALTIMORE – Complete Omics today announced that Hui Zhang, PhD, has joined the Company’s Board of Advisors, effective July 1st, 2021. Dr. Zhang joins the Complete Omics Board of Advisors with extensive experience in basic and clinical proteomics and cancer research.
Dr. Hui Zhang is Professor of Pathology, Oncology, Chemical and Biomolecular Engineering, and Urology, and the Director of Mass Spectrometry Core Facility and Center for Biomarker Discovery and Translation in Johns Hopkins University.
Dr. Zhang specializes in proteomics, and she studies protein modifications on the proteome scale and the effects of protein modifications on protein functions and diseases. She is the inventor of the famous N-Glycosylation proteomics pipeline which is widely used in biomedical researches for this essential post-translational modification. For the past few years, her laboratory has further developed several novel glycoproteomic and glycomic technologies to study structures of cell surface glycoproteins and secreted glycoproteins. Currently, researchers in her group focus on understanding the functions of protein modifications in biology and human diseases.
Dr. Zhang’s laboratory is one of the three founding laboratory members of the Clinical Proteomic Tumor Analysis Consortium (CPTAC). CPTAC is organized under NIH and NCI in the USA, and it represents the US national commitment to fostering clinical proteomics discoveries and applications by the US government. Research papers published by Dr. Zhang and her colleagues in CPTAC represent the gold standard for clinical proteomics researches and the best knowledge of human beings on cancer-related clinical proteomics. Three typical examples of her pioneer works in CPTAC are as follows:
- Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell. 2016 Jul 28;166(3):755-765.
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 2019 Oct 31;179(4):964-983.e31.
- Proteogenomic characterization of pancreatic ductal adenocarcinoma.Cell. 2021 Sep 16;184(19):5031-5052.e26.
In recent years, in addition to her contribution to the CPTAC project, Dr. Zhang has published her clinical proteomics works repeatedly on top profile journals, including Cell, Nature, Nature Biotechnology, Nature Protocols, Cancer Cell, PNAS, etc. Dr. Zhang’s clinical proteomics discoveries have been cited over 20,000 times.
“We are extremely grateful to welcome Dr. Zhang to our Board of Advisors,” said Qing Wang, Founder and Chief Executive Officer of Complete Omics. “Dr. Zhang’s leadership in the field of proteomics and her deep knowledge and experience in translational proteomics research and cancer diagnostics bring tremendous value to Complete Omics. Her expertise and guidance will greatly benefit Complete Omics this year and in the years to come.”